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A phase I trial of infusing anti-CD3 anti-CD20 bispeciﬁc antibody (CD20Bi) armed activated Tcells (aATC) was
conducted in high-risk/refractory non-Hodgkin’s lymphoma patients to determine whether aATC infusions are
safe, affect immune recovery, and induce an antilymphoma effect. Ex vivo expanded ATC from 12 patients were
armed with anti-CD20 bispeciﬁc antibody, cryopreserved, and infused after autologous stem cell trans-
plantation (SCT). Patients underwent SCT after high-dose chemotherapy, and aATC infusions were started on
dayþ4. The patients received 1 infusion of aATC per week for 4weeks after SCT with doses of 5,10,15, and 20
109. aATC infusions were safe and did not impair engraftment. The major side effects were chills, fever,
hypotension, and fatigue. The mean number of IFN-g Enzyme-linked Immunosorbent Spots (ElSpots) directed
at CD20 positive lymphoma cells (DAUDI, P ¼ .0098) and natural killer cell targets (K562, P < .0051) and the
mean speciﬁc cytotoxicity directed at DAUDI (P ¼ .037) and K562 (P ¼ .002) from pre-SCT to post-SCT were
signiﬁcantly higher. The increase in IFN-g EliSpots from pre-SCT to post-SCT in patients who received armed
ATC after SCT were signiﬁcantly higher than those in patients who received SCT alone (P ¼ .02). Serum IL-7,
IL-15, Macrophage inﬂammatory protein (MIP)-1 beta, IP-10, MIP-1a, and Monokine induced by gamma
interferone increased within hours after infusion. Polyclonal and speciﬁc antibodies were near normal
3 months after SCT. aATC infusions were safe and increased innate and speciﬁc antilymphoma cell immunity
without impairing antibody recovery after SCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Arming with anti-CD20 bispeciﬁc antibody (CD20Bi) makes
High-dose chemotherapy (HDC) followed by autologous
stem cell transplantation (SCT) induces complete responses
in patients with high-risk, refractory, or relapsed non-
Hodgkin’s lymphomas (NHLs) [1-6]. In the rituximab era
where rituximab added to cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) improves progression-
free survival over CHOP [7], only 10% of chemosensitive
patients who do not achieve a complete response or who are
in relapse remain disease free with salvage chemotherapy
alone [8]. In these patients, salvage therapy should be
consolidated with HDC followed by SCT [9]. These high-risk
refractory or relapsed patients could beneﬁt from targeted
T cell immunotherapy approaches that provide anti-
lymphoma activity after SCT.
Rituximab (a chimeric monoclonal antibody directed at
CD20þ lymphoma cells) kills CD20þ cells by complement-
mediated cytotoxicity, antibody-dependent cell-mediated
cytotoxicity, and the induction of apoptosis [10-13]. Our
approach exploits the nonemajor histocompatibility
complex restricted cytotoxicity of anti-CD3 activated T cells
(ATC) [14-17] by redirecting their cytotoxicity to tumor
targets by arming ATC with CD20 bispeciﬁc antibodies [18].dgments on page 932.
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13.03.010every ATC into a CD20-speciﬁc cytotoxic lymphocyte.
Our preclinical studies show that CD20Bi armed ATC
(aATC) signiﬁcantly enhanced lysis of CD20 antigen express-
ing B9C (immortalized normal B cell line), Raji (Burkitt
lymphoma line), and ARH-77 (rituximab-resistant multiple
myeloma cell line). Mean speciﬁc cytotoxicity directed at B9C
ranged from41% to65%ateffector-to-target ratios from6.25:1
to 25:1, and CD20Bi aATC cultured with lymphoma B9C cells
produced signiﬁcantly more IFN-g than unarmed ATC
cultured with B9C (P ¼ .0103) [18]. The ability of aATC to lyse
ARH-77 cells suggested that CD20Bi aATC may be clinically
effective for resistant or refractory NHL after HDC and SCT.
In this phase I clinical trial involving multiple infusions of
aATC after SCT, we asked whether T cells can be expanded
from the peripheral blood mononuclear cells (PBMCs) ob-
tained from heavily pretreated NHL patients to produce ATC
that could be infused without dose-limiting toxicities (DLTs)
and whether infusions of aATC induce endogenous anti-
lymphoma cytotoxic T lymphocyte responses without
impairing immune reconstitution. The primary objective of
this study was safety, and secondary objectives included
feasibility of the T cell expansions and evaluation of immune
responses.
METHODS
Trial Design
We enrolled patients between 18 and 70 years of age with high-risk or
refractory, histologically conﬁrmedCD20þNHLat KarmanosCancer Institute
Transplantation.
Figure 1. (A) Treatment schema. The chemotherapy preparative regimen involved BEAM, which consisted of carmustine 300 mg/m2  1 dose at day 7, etoposide at
100 mg/m2 every 12 hours and cytarabine 100 mg/m2 every 12 hours on days 6 through 3, and melphalan 140 mg/m2  1 dose at day 2, day of rest on day 1,
and transplantation on day 0. (B) Process of heteroconjugation of anti-CD3 with rituximab. Step 1 shows cross-linking of Traut’s reagent to anti-CD3 (OKT3) mAb and
the cross-linking of Sulpho-SMCC to anti-CD20 (rituximab); step 2 shows the heteroconjugation of the cross-linked anti-CD3 with the cross-linked rituximab; and
step 3 shows formation of anti-CD3  anti-CD20 BiAb (CD20Bi). (C) SDS-PAGE gel of the parent monoclonal antibodies and the heteroconjugated CD20Bi. Lane 1:
Protein ladder; lane 2: anti-CD20 mAb; lane 3: anti-CD3 mAb; lane 4: CD20Bi. (D) The schema shows T cell expansion after leukapheresis of the patient, harvesting,
and arming of ATC with CD20Bi, cryopreservation in aliquots for infusions after SCT at the designated time points for the treatment schema shown in A.
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tained before enrollment on consent forms approved by the Wayne State
University institutional review board and the US Food and Drug Adminis-
tration. Protocol WSU 2007-023 was conducted per guidelines from the
Declaration of Helsinki. aATC were produced under IND BB-11746, and the
study was monitored by the Karmanos Cancer Institute data safety moni-
toring committee. Exclusion criteria were forced expiratory volume in 1
second and Carbon monoxide diffusing capacity (DLCO) < 45%, creatinine >2.0 mg/dL or creatinine clearance< 60 mL/min, direct bilirubin> 2.0 mg/dL,
serum glutamic oxaloacetic transminase or serum glutamic pyruvic trans-
minase > 2.5 times the upper limit of normal or history of severe hepatic
dysfunction, left ventricular ejection fraction < 40% by Multi-Gated Acqui-
sition Scan (MUGA) or echocardiography at rest, active infection, human
immunodeﬁciency virus antibody positivity, and Eastern Cooperative
Oncology Group ( ECOG) performance status >2 or Karnofsky Performance
Status (KPS) <60%.
Table 1
Clinical Characteristics
Age Dx Sex Prior Chemotherapy Regimens
Prior to SCT
CD 34 106/kg Planned aATC
Dose 109
Actual aATC
Dose 109
Status
at SCT
Status at
90 days
C-IT* Survival
(days) (Dy/Az)
1 54 DLBCL M RCHOP X4, RICE X2 2 2.6 20 18.4 PRF PD 56 days N 107 (D)
2 53 DLBCL F RCHOP X8, RICE X2 2 8.4 20 17.15 PRF PD 30 days Y 111 (D)
3 67 DLBCL F RCHOP X6, RICE X2 2 7.1 40 38.64 PR CR Y 1294 (A)
4 55 FCL F RCHOP X6, RICE X2 2 3.2 40 37.44 CR2 PD 60 days Y 126 (D)
5 61 DLBCL M R-CHOP X8, RICE X2 2 6.1 40 37.28 CR2 PD 52 days Y 112 (D)
6 59 DLBCL M RCHOP X6, RCEOP X4 2 6.0 60 60 CR2 CR Y 984 (A)
7 56 DLBCL F RCHOP X8, RICE X2 2 2.6 60 45 CR2 PR Nx 987 (A)
8 67 DLBCL M RCHOP X6 1 12.3 60 61.6 CR1U CR Y 914 (A)
9 47 DLBCL M R X4, RCHOP X6 2 4 60 48.92 PR1 PD 67 days Y 184 (D)
10 59 DLBCL F RCHOP X8, RICE X4 2 9.5 80 82 CR2U CR Y 781 (A)
11 46 DLBCL M RCHOP X8, RICE X2 2 6.0 80 67.64 CR2 CR Y 718 (A)
12 61 DLBCL M RCVP X2, RCHOP X6 2 2.5 80 78.04 PR CR Y 711 (A)
DLBCL indicates Diffuse large B cell lymphoma; FCL, Follicular lymphoma; R, rituximab; RCHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and
prednisone; RCVP, rituximab-cyclophosphamide, vincristine, and prednisone; RICE, rituximab, ifosphamide, carboplatin, and etoposide; CVAD, cyclophos-
phamide, vincristine, adriamycin, and dexamethasone; RCEOP, rituximab-cyclophosphamide, etoposide, vincristine, and prednisone; CR, clinical remission; PR,
partial response; PRF, progressive refractory disease; PD, progressive disease.
* C-IT: Immunotherapy completed yes (Y) or no (N).
y Alive (A) or dead (D).
z Survival days after SCT.
x Received 3 out of 4 infusions.
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doses of 5, 10, 15, and 20  109 aATC were given once a week for 4 weeks
beginning on day þ4 after SCT for total doses of 20, 40, 60, and 80  109
(Figure 1A). PBMC from 8 patients (5 NHL and 3 multiple myeloma patients)
who received unmanipulated autologous SCT alone on Protocol WSU 2007-
046 were tested as a control patient group.
Leukapheresis and T Cell Expansion
PBMCs were collected by leukapheresis, activatedwith anti-CD3 (OKT3),
and expanded in IL-2 [19,20] (Figure 1D). CD20Bi was produced as previ-
ously described (Figure 1B, C) [21] (see Supplemental Appendix).
Mobilization of Stem Cells
Patients received granulocyte colony-stimulating factor (G-CSF) stimu-
lation to obtain a minimum CD34þ cell dose of 2  106 cells/kg.
Preparative Regimen and Transplantation
HDC consisted of i.v. carmustine (300 mg/m2 for 1 dose on day 7),
etoposide (100 mg/m2 every 12 hours on days 6 through 3), cytarabine
(100 mg/m2 every 12 hours on days 6 through 3), and melphalan (140
mg/m2 for 1 dose at day2) (BEAM) followed by a day of rest on day1 and
transplantation on day 0 (Figure 1A).
Infusions of aATC
On the day of infusion after SCT, cryopreserved aATC were thawed and
infused at the bedside. aATC were given over 5 to 15 minutes after pre-
medicating patients with diphenyhydramine and acetaminophenwith close
monitoring of vital signs and O2 saturations.
Phenotyping, Speciﬁc Cytotoxicity, IFN-g EliSpots, Serum Cytokines, and
IgG and Anti-Tetanus Toxoid Antibody Levels
Speciﬁc cytotoxicity was performed using fresh PBMCs mixed with 51Cr-
labeled DAUDI and K562 cells [18]. IFN-g Elispots were used to measure
CD8-mediated memory cytotoxic T lymphocyte activity and CD4-mediated
helper responses [22]. Cytokines were measured by Luminex Array and
polyclonal IgG and anti-tetanus toxoid (anti-TT) levels were measured by
ELISA (see Supplemental Appendix) [23].
Statistical Analyses
Wilcoxon signed-rank test was used to examine the median of the
change at each time point from prestudy in phenotyping, cytotoxicity
against DAUDI, and K562. For Elispots against DAUDI and K562, the differ-
ences between pre-SCT and the observed peak value within 3 months post-
SCT were examined using Wilcoxon signed-rank test. Change in numbers of
IFN-g EliSpots at post-SCT from pre-SCT were compared between patients
who received SCT alone with the study patients who received SCT and aATC
using the Wilcoxon Mann-Whitney test. Mixed effects models were used to
examine the potential trend of phenotyping, cytotoxicity, and EliSpot
measurements over time. Detailed methods are provided in the
Supplemental Appendix.RESULTS
Patient Characteristics
Table 1 summarizes the patient characteristics,
prior therapy, and disease status at SCT. Most patients had
relapsed after ﬁrst-line chemotherapy with rituximab,
cyclophosphamide, adriamycin, vincristine and prednisone
(R-CHOP) or did not achieve a complete remission after ﬁrst-
line chemotherapy. All but 1 patient with follicular
lymphoma had diffuse large B cell lymphoma who had
received 2 regimens before SCT (Table 1). Some patients could
not achieve a complete response after salvage therapy with
rituximab, ifosphamide, carboplatin and etoposide (RICE) and
underwent transplantation with refractory disease. Table 1
shows the disease status at the time of SCT and at 90 days
after SCT. All patients had received multiple rounds of
rituximab-containing therapy.
Stem Cell Mobilization
Table 1 shows the doses of CD34þ cells infused into the
patients. One patient required G-CSF mobilization twice and
a bone marrow harvest to obtain enough CD34þ cells for the
SCT.
Engraftment of Neutrophils, Lymphocytes, and
Monocytes
The median day of neutrophil engraftment (neutrophil
count  500/mm3) was day 13. Figure 2A summarizes the
mean absolute white blood cell count and lymphocyte,
neutrophil, and monocytes counts for the 12 patients during
the ﬁrst 20 days after SCT. All patients engrafted without
G-CSF, except 1 patient who had slow engraftment and
engrafted 28 days after SCT with addition of G-CSF.
ATC Characteristics
The planned aATC dose, the actual aATC dose, the
percentage of the target dose of aATC dose administered,
time to progression, and survival are presented in Table 1.
The mean percent (SD) viability was 91.1%  4.18% and the
mean proportion (95% conﬁdence interval) of CD3, CD4, and
CD8 cells were 96.5% (21.7, 76.8), 78.2% (11.3, 57.1), and 48.2%
(9.6, 52.0), respectively (Table 2). The CD20Bi aATC product
was tested for the viability and speciﬁc cytotoxicity against
the target cell line (DAUDI). CD20Bi aATC exhibited a mean
Figure 2. Engraftment. (A) Daily mean absolute white blood cell count,
lymphocyte, absolute neutrophil, andmonocyte counts for 12 patients. (B) Flow
cytometry performed on PBMCs from patients at the indicated time points after
SCT shows mean proportions of CD3þ, CD4þ, and CD8þ T cells after SCT. (C)
Overall survival of 12 patients transplanted for NHL. The Kaplan-Meier curve
is presented for the entire population (All patients), the subgroup of patients
who underwent transplantation in remission (REM), and the subgroup of
patientswhowere transplantation inpartial remission or had refractory disease
(PR þ Ref).
Table 2
Phenotyping of the Harvest Product
Harvest Product Mean (%) Range (%)
CD3þ 96.5 68.9-98.7
CD3/4þ 78.2 33.3-90.8
CD3/8þ 48.2 17.7-86.8
CD4/25þ 59.3 19.6-88.2
CD8/25þ 30.9 4.1-62.6
CD3þ(16/56)þ 3.3 .4-16.9
CD3(16/56)þ 11.5 .9-53.3
CD19þ .4 .03-5.8
CD20þ .1 .01-.5
CD4þ(45RA/45ROþ) 95.2 76.1-99.4
CD8þ(45RA/45ROþ) 90.8 68.2-98.1
CD4þ(45RAþ/45RO) .4 .1-2.9
CD8þ(45RAþ/45RO) 1.1 .3-12.5
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to 25%) directed at CD20þ DAUDI targets at an effector-
to-target ratio of 25:1 by 51Cr release cytotoxicity assay.
Infusions of aATC
The median total dose of aATC delivered was 6.7  1010
(95% conﬁdence interval of 4.24, 6.73  1010). The maximumtolerated dose was not reached, and there were no DLTs. The
most frequent side effects included fever, chills, malaise,
nausea and/or vomiting, tachycardia, hypotension, headache,
transient hypoxia, hypertension, and dyspnea (Table 3).
Lymphocyte Recovery
The mean (N ¼ 12) proportion of CD3þ and CD4þ cells
was 22% and 19% at 2 weeks after SCT, respectively. By
1month after SCT, themean proportions of CD3þ, CD4þ, and
CD8þ cells reached 35%, 22%, and 20%, respectively, with
a CD4/CD8 ratio ofw1.0. The median percent CD3, CD4, and
CD8þ cells are shown in Figure 2B at the indicated time
points. The CD8þ population increased between 4 and
8 weeks after SCT. CD19þ B cells were present but low at
0.75% and 0.27% at 2 and 3 months, respectively, and
recovered to 3.43% and 3.85% at 6 and 12 months, respec-
tively. The proportions of CD20þ cells followed the same
pattern as CD19þ cells at indicated time points.
Clinical Responses
Figure 2C shows the Kaplan-Meier estimates for all
patients and for 2 subgroups (patients who were in remis-
sion at the time of SCT and patients who had refractory or
persistent disease at the time of SCT). The median overall
survival for the entire group was not achieved at a median
follow-up of 24 months. One patient withdrew after 2 aATC
infusions due to progression of disease, and 1 patient with-
drew after 3 infusions due to discomfort from the infusions.
Both patients were included in Kaplan-Meier estimates
because they received aATC.
PBMC-Mediated Cytotoxicity after SCT
PBMCs from leukapheresis at baseline and from periph-
eral blood at indicated time points (2 weeks to 3 months
post-SCT) were tested in cytotoxicity assays against DAUDI or
K562 cells. The highest levels of cytotoxicity by PBMC
directed at DAUDI post-SCT (2 weeks to 3 months post-SCT)
was signiﬁcantly higher (P¼ .037,Wilcoxon signed-rank test)
compared with pre-SCT PBMCs. Cytotoxicity against K526
targets was also signiﬁcantly (P ¼ .002, Wilcoxon signed-
rank test) higher at 2 weeks to 3 months post-SCT than at
baseline PBMCs. These data show that aATC infusions
enhanced both antilymphoma and natural killer (NK) activ-
ities (Figure 3A).
IFN-g EliSpots
Short-term IFN-g EliSpot (surrogate markers for CD8þ
cytotoxic T lymphocytes and CD4þ helper activity) responses
to DAUDI or K562 stimulation were studied in 11 patients
Table 3
Toxic Reaction Incidence and Grade by Dose Level
Dose Adverse Event N (%) Grade 1 Grade 2 Grade 3 Grade 4
Level 1*,y (40Bz total) Nausea and vomiting 3 (100) 4 3
Diarrhea 1 (33.3) 2
Malaise 1 (33.3) 1 1
Atrial rhythm 1 (33.3) 2
Fever 3 (100) 3 7
Headache 1 (33.3) 2
Chills 2 (66.6) 7
Hypotension 2 (66.6) 4
Hypertension 1 (33.3) 1
Sinus tachycardia 1 (33.3) 1
Level 2* (60Bz total) Chills 4 (100) 1x 9x
Rhythm, ventricular 2 (50) 4x 1x
Hypotension 1 (25) 1x
Fever 3 (100); 4 (100) 1 8x 3
Headache 0 (0); 1 (33.3) 2x
Malaise 2 (66.6); 2 (66.6) 7
Nausea 1 (33.3); 1 (33.3) 3
Level 3*,y (80Bz total) Chills 2 (66.6) 5 3
Malaise 2 (66.6) 8 4
Rhythm, ventricular 3 (100) 4
Hypotension 3 (100) 3 2
Fever 3 (100) 4 8
Pulmonary 1 (33.3) 1 1
Headache 2 (66.6) 6
Pain 3 (100) 4
N is the number of patients experiencing adverse event (% of total at the dose level).
* Dose level on the new version of the protocol that was approved March 3, 2008.
y Total number of episodes by grade at the dose level.
z B indicates dose in billions.
x These are inclusive of 1 patient, who received only 3 of 4 infusions.
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levels of IFN-geproducing T cells between 2 weeks to 3
months post-SCT. IFN-g Elispots stimulated with DAUDI
were signiﬁcantly higher (P ¼ .0098, Wilcoxon signed-rank
test) than that seen in pre-SCT values (Figure 3B, left).
Figure 3B, right, shows IFN-g EliSpot responses to K562 cells
that were consistently higher at time points post-SCT over
the baseline (P < .005, Wilcoxon signed-rank test). To
determine whether the responses post-SCT were due to
“immunologic” noise as a result of the SCT process alone, we
tested a comparable group of patients who received SCT
alone and compared their change in numbers of IFN-g Eli-
Spots obtained pre-SCT and post-SCT with the study patients
who received SCT and aATC (Figure 3B). The increases in
IFN-g Elispots from pre-SCT to post-SCT directed at DAUDI
was signiﬁcantly higher in patients who received SCT and
aATC (P¼ .02, Wilcoxon Mann-Whitney Test two-sided exact
P value) during the same time interval (Figure 3B). These data
show that infusions of aATC induced highly signiﬁcant
increases in antilymphoma cell EliSpots (DAUDI) as well as
increases in antieNK cell activity directed at K562.
Levels of Cytokines and Chemokines
In 4 patients, steady-state serum levels of IL-2R and IL-12
(Figure 4A, top) and IFN-geinduced chemokines CXCL10 and
CXCL9 (Figure 4A, bottom) were elevated above baseline. IL-
2R was signiﬁcantly higher (P < .05) in 1 of 4 patients at 3
months and IL-12 was signiﬁcantly higher at 1 and 3 months
(P < .045 and P< .042, respectively) post-SCT compared with
pre-SCT serum levels in 2 of 4 patients, respectively. IFN-
geinduced chemokines CXCL10 (P < .027 and P < .031) and
CXCL9 (P < .023 and P < .047) were also signiﬁcantly higher
at 3 months post-SCT comparedwith pre-SCT serum levels in
2 of 4 patients, respectively. An aATC infusion given 10 days
after SCT showed peak levels of Th1 cytokines andchemokines between 1 and 4 hours, (Figure 4B). Levels of
IFN-g and IL-12 increased at 4 hours above baseline
(Figure 4B, bottom).IgG and anti-TT levels
Figure 4C andD shows serum IgG and anti-TT levels before
and 3 months after SCT, respectively. The mean levels of IgG
before and after SCT were 9.5  1.5 mg/mL and 8.0  1.5 mg/
mL, respectively. Themean serum levels of anti-TT before and
after SCT were 11.4  7.8 mg/mL and 12.8  10.1 mg/mL,
respectively.DISCUSSION
In our phase I trial, patients who received 4 doses of 20 
109 aATC given in the ﬁrst 30 days after SCT experienced no
DLTs. Infusions of aATC induced a Th1 cytokine pattern in the
serum that was associated with increased chemokine levels.
There were signiﬁcantly higher levels of speciﬁc cytotoxicity
and IFN-g EliSpots in PBMCs directed at DAUDI and K562
after SCT than at baseline levels before SCT. More impor-
tantly, the increase in antilymphoma IFN-g EliSpots was
signiﬁcantly higher in the phase I group of patients who
received aATC than the group of patients who received SCT
alone. Although there was a transient decrease in the
numbers of CD19þ cells in the circulation, infusions of aATC
did not impair the recovery of IgG and anti-TT levels at
100 days after SCT. It is not clear whether the cytokine/che-
mokine changes observed during the aATC infusions were
due to the bispeciﬁc antibody aATC or the perturbation
induced by infusion of unarmed ATC alone. It is likely that
both ATC and the CD20Bi arming of ATC contributed to the
enhanced amounts of the serum cytokine/chemokine
changes. Further studies are needed to determine which
component contributed the most.
Figure 3. (A) Cytotoxicity directed at DAUDI (left) and K562 (right). Fresh PBMCs from patient who received aATC were tested in 51Cr release cytotoxicity assay 2
weeks to 3 months post-SCT. (B) IFN-g EliSpots against DAUDI (left) and K562 (right) in patients who received aATC and SCT (SCT þ IT) and patients who received SCT
alone (SCT alone). Fresh PBMCs for patients who received aATC and SCT that were plated onto DAUDI and K562 targets (right two columns in each panel). Fresh
PBMCs for patients who received SCT alone were plated onto DAUDI and K562 targets (left two columns in each panel).
L.G. Lum et al. / Biol Blood Marrow Transplant 19 (2013) 925e933930Clinical efﬁcacy could not be assessed because of small
sample size, short follow-up time, disease status at the time of
transplantation, prior chemotherapy, and the conditioning
regimen in a heterogeneous patient population. Furthermore,
correlates between survival and cytotoxicity, IFN-g EliSpots,
dose of aATC, and product cytotoxicity were not signiﬁcant.
The clinical picture was consistent with a mild clinically
manageable “cytokine storm syndrome.” With the exception
of 1 patient who was not adequately hydrated and needed
observation in the intensive care unit during i.v. hydration,
the patients received their infusions in the bone marrow
transplantation unit or in the outpatient bone marrow
transplantation clinic.
Because most patients previously received rituximab in
initial chemotherapy and salvage regimens, it is likely that
CD20-resistant clones might have developed. aATC may not
only overcome CD20 resistance but could also kill CD20þ
targets in the presence of rituximab [18]. The interactive
combination of dosing and tumor burden could lead to more
or less interference with CD20Bi aATC targeting. However,
the last dose of potentially interfering rituximab would have
been given more than 4 weeks before SCT. If there was
residual rituximab on the lymphoma or in the circulation, it
is likely CD20Bi aATC could still kill the CD20 targets [18].
Therefore, killing by CD20-redirected ATC may further
reduce the tumor burden and induce endogenous CD20-
speciﬁc antilymphoma responses.
The use of rituximab has been encouraging but contro-
versial in terms of overall survival beneﬁt when it has been
used in preparative regimens or as consolidation after HDC
and SCT to reduce the incidence of relapse [2,24-31].Rituximab consolidation after SCT may have improved
outcomes for patients with aggressive B cell NHL
[25,26,28,31]. Studies suggest that immunity directed at
pneumococcal conjugate, human telomerase reverse tran-
scriptase (hTERT), and inﬂuenzae after autologous SCT can be
manipulated before and after SCT by adoptive transfer of T
cells [32-34]. Therefore, adoptive transfer aATC may provide
a similar antilymphoma effect.
Because ATC could be expanded up to 80  109 from
a single leukapheresis from heavily pretreated NHL patients,
it is clear that ex vivo lymphocyte expansion is feasible. The
cytotoxicity by PBMCs after SCT (2 weeks to 3 months)
directed at DAUDI cannot be explained by the infused aATC
because the mean cytotoxicity of aATC product was 12.1%,
the proportion of aATC that would circulate after an infusion
of 40  109 aATC no more than 4%. Because the amount of
cytotoxicity would be very low due to a greater than 20-fold
dilution of aATC, the cytotoxicity and IFN-g EliSpots detected
at indicated time points post-SCT were likely derived from
endogenous lymphocytes. The Th1 and T cell proliferative
cytokines induced by aATC infusions may have provided
support for the induction of endogenous antilymphoma
activity.
Infusions of a CD4-enriched aATC product likely led to the
shift toward a normal CD4/CD8 ratio early after SCT. Infused
aATC could be detected up to 7 days, whereas IL-7 and IL-15
known to support T cell growth were detected. There was
a signiﬁcant increase in speciﬁc IFN-g EliSpots to lymphoma
targets 100 days after SCT above that seen pre-SCT (P <
.0098). The increases in speciﬁc cytotoxicity directed at
DAUDI targets did not correlate with increases in IFN-g
Figure 4. Changes in serum cytokines and chemokines. (A) Infusions of aATC-induced cytokines and chemokines. aATC infusions enhanced cytokines IL-2R and IL-12
and IFN-geinduced chemokines CXCL10 (IP-10) and CXCL9 (MIG) in 4 patients at indicated time points (*P < .05). (B) Top: sequential mean (SD) fold increase in
serum levels for T cell proliferation inducing cytokines IL-2, IL-7, and IL-15 (left) and serum chemokines MIP-1b and MIP-1a and IFN-geinduced chemokines CXCL10
(IP-10) and CXCL9 (MIG). Bottom: sequential serum levels for IFN-g and IL-12. Serum samples were analyzed in 3 patients after the second infusion at the designated
times. (C) Transfer and reconstitution of IgG and anti-TT. The results for individual patients are presented. Total IgG was tested before and at 3 months after SCT to
determine the levels of IgG transferred in the stem cell product. aATC infusions did not affect total IgG levels in the serum. (D) Anti-TT before and at 3 months after
SCT were analyzed to determine whether the levels of speciﬁc anti-TT transferred in the stem cell product.
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of IFN-g EliSpots may be not be due to IFN-geproducing
cytotoxic CD8þ cells but rather to IFN-gesecreting CD4þ
helper T cells. These data support the argument that armed T
cell infusions induced both cytotoxic T lymphocyte and
helper antilymphoma responses. Correlations of immune
responses or aATC doses with clinical responses could not be
assessed because of the small sample size.
NK activity directed at K562 was signiﬁcantly enhanced
over pre-SCT levels in both cytotoxicity and IFN-g EliSpots,
and these increases persisted up to 100 days after SCT. These
data suggest that infusions of aATC stimulated recovery of
innate immunity. Evaluations of NK activity in contempora-
neous NHL and multiple myeloma patients did not show
such a pattern of immune recovery.
Although targeting CD20þ B cells decreased the number
of circulating CD20þ cells during ﬁrst 6 months after SCT,
there were normal levels of IgG and anti-TT at 3 months after
SCT. Previous studies have reported that rituximab consoli-
dation after autologous SCT for NHL may prolong hypo-
gammaglobulinemia, impair B cell reconstitution, and
deplete memory B cells [35-40]. In the absence of intrave-
nous gamma globulin supplementation, B cells or CD20
negative plasma cells must produce IgG or anti-TT. The
memory B cells or plasma cells in the stem cell graft were
capable of reconstituting and producing normal levels of IgG
and anti-TT without being depleted by aATC infusions.
Because ATC may provide helper activity to B cells for anti-
body synthesis, aATC infusions may also accelerate hemato-
poietic recovery [41-43]. These data suggest that aATC
infusions may provide helper activity to B cells transferred in
the stem cell inoculum despite the apparent transient
depletion of B cells.
There are major differences between the approach using
gene transduction of chimeric antibody receptors into anti-
CD3/anti-CD28 ATCs [44,45] and the approach using anti-
CD3/IL-2 ATCs armed with bispeciﬁc antibodies [18,21].
Anti-CD3/anti-CD28 coATCs are transduced with scFv and
signal transduction elements that are designed to activate
upon tumor engagement, rapid expansion, and the devel-
opment of a sustained antileukemia effect [22,46]. In
contrast, aATC are designed to mediate immediate cytotox-
icity, undergo short-term proliferation, and release Th1
cytokines and chemokines at the tumor site to recruit
endogenous immune cells, leading to in situ vaccination [22].
The complex effort exerted to provide proof-of-principle
using chimeric antibody receptor transduced T cells has
been labor intensive [47] and costly; however, recent
successes suggest the chimeric antibody receptor approach
may be successful with liquid tumors [48].
In summary, aATC infusions were safe in patients after
SCT and induced signiﬁcant increases in cytotoxicity and
IFN-g EliSpot anti-DAUDI activity as well as increases in
innate immunity above that seen in patients who received
SCT alone. The design of this phase I trial and follow-up time
did not permit evaluation of clinical efﬁcacy. Although infu-
sions of aATC enhanced antilymphoma activity, T cell helper
activity, and NK activity without impairing B cell functions,
there were no correlations between clinical efﬁcacy and
immune responses. The current study provides a strong
rationale for initiating phase II trials to conﬁrm the ability of
CD20Bi aATC to enhance antilymphoma effects and accel-
erate immune reconstitution in patients after SCT for high-
risk/refractory NHL.ACKNOWLEDGMENTS
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